Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma.

S Zhan; D N Shapiro; L J Helman

doi:10.1172/JCI117344

Molecular Oncology Section, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Zhan, S. in: JCI | PubMed | Google Scholar

Molecular Oncology Section, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Shapiro, D. in: JCI | PubMed | Google Scholar

Molecular Oncology Section, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Helman, L. in: JCI | PubMed | Google Scholar

Published in Volume 94, Issue 1 on July 1, 1994
J Clin Invest. 1994;94(1):445–448. https://doi.org/10.1172/JCI117344.
© 1994 The American Society for Clinical Investigation

Published July 1, 1994 - Version history

The insulin-like growth factor II (IGF2) gene is exclusively silent at the maternal allele in the mouse as well as in normal human tissues and is expressed at a high level in rhabdomyosarcoma (RMS). We report here that the normally imprinted allele of the IGF2 gene is activated in RMS tumors as well as in one RMS cell line. Since overexpression of IGF2 has been shown to be important in the pathogenesis of RMS, our data suggest that loss of imprinting (LOI) may lead to overexpression of IGF2 and play an important role in the onset of RMS. Furthermore, embryonal RMS usually has loss of heterozygosity (LOH) with paternal disomy of the IGF2 locus. One informative embryonal RMS tumor evaluated in this study was heterozygous at the IGF2 allele and had LOI, raising the possibility that LOI may be the functional equivalent of LOH in this tumor with both events leading to overexpression of IGF2.

Images.

Click on an image below to see the page. View PDF of the complete article